Table 1.
Demographic Characteristics of Study Participants
| Characteristic (n = 3056) | No. (%) or Median (IQR) |
|---|---|
| Demographics | |
| Age, median (IQR), y | 44 (38–51) |
| Women | 827 (27%) |
| Race | |
| White | 1519 (50%) |
| Black | 696 (23%) |
| Hispanic | 570 (19%) |
| Asian | 200 (7%) |
| Other | 71 (2%) |
| Country of origin | |
| Non-US | 1859 (61%) |
| US | 1197 (39%) |
| HIV exposure group | |
| MSM | 1498 (49%) |
| Heterosexual | 1156 (38%) |
| IDU | 239 (8%) |
| Other | 163 (5%) |
| BMI, median (IQR), kg/m2 | 24.5 (22.1–27.4) |
| Smoking (current) | 1138 (37%) |
| HBV infection | 69 (2%) |
| HCV infection | 130 (4%) |
| Time since start of ART, y | |
| <1 | 72 (2%) |
| 1–5 | 1082 (35%) |
| >5 | 1895 (62%) |
| Antiretroviral regimen | |
| NNRTI-based | 1388 (45%) |
| PI-based | 1164 (38%) |
| Other | 504 (16%) |
| Baseline CD4+ T-cells, median (IQR), cells/mm3 | 649 (496–842) |
| Nadir CD4+ T-cells, median (IQR), cells/mm3 | 230 (136–329) |
| HIV VL <50 copies/mL | 2371 (78%) |
| Adherence (7-d) | |
| 100% adherence | 2652 (87%) |
| Suboptimal adherence | 404 (13%) |
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; IDU, injection drug users; IQR, interquartile range; MSM, men who have sex with men; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.